Azetukalner not checked

Xenon Pharmaceuticals Inc. · XEN1101

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
8 active
11 in total · 9 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.”In the company’s words, NCT06922110 on ClinicalTrials.gov
Tested for
Major Depressive Disorder (2 trials), Bipolar Disorder (2 trials), Bipolar Depression (2 trials), Bipolar I Disorder (2 trials), Bipolar II Disorder (2 trials), Focal Epilepsy (2 trials), Primary Generalized Tonic-Clonic Seizures, Focal Onset Seizures and 1 more
Main trialPhase 3
“X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).”In the company’s words, NCT06922110 on ClinicalTrials.gov
Other names
XEN1101

Other drugs for Major Depressive Disorder

All 36 drugs for Major Depressive Disorder

Coming up7

Changes2

Last 90 days

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Jan 2027 An Open-Label Study of Azetukalner in Major Depressive Disorder
Phase 3Recruiting Apr 2027 A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Phase 3Active, not recruiting May 2027 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Phase 3Recruiting Jan 2028 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Phase 3Active, not recruiting Jun 2028 A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Phase 3Active, not recruiting Jun 2029 An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Phase 3Enrolling by invitation Apr 2033 An Open-label Study of XEN1101 in Epilepsy
Phase 2Active, not recruiting 2 Sep 2021 A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Phase 3Completed 12 Jan 2026 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Phase 3Terminated 28 Oct 2026 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Phase 2Completed 18 Sep 2023 A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Azetukalner

Following is part of Solo: you see every change to Azetukalner the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in